MARKET

CWBR

CWBR

CohBar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.490
-0.030
-1.97%
Closed 16:00 07/10 EDT
OPEN
1.470
PREV CLOSE
1.520
HIGH
1.500
LOW
1.410
VOLUME
98.96K
TURNOVER
--
52 WEEK HIGH
4.250
52 WEEK LOW
0.8700
MARKET CAP
58.74M
P/E (TTM)
-4.4624
1D
5D
1M
3M
1Y
5Y

CWBR News

More
CohBar (CWBR) Investor Presentation - Slideshow
Seeking Alpha - Article · 3d ago
CohBar Resumes CB4211 Phase 1b Clinical Trial
GlobeNewswire · 5d ago
CohBar Resumes CB4211 Phase 1b Clinical Trial Of Lead Candidate For treatment Of Nonalcoholic Steatohepatitis And Obesity
CohBar Resumes CB4211 Phase 1b Clinical Trial MENLO PARK, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat
Benzinga · 5d ago
CohBar to Present at Sachs Novel Coronavirus Investment Forum
GlobeNewswire · 6d ago
CohBar Added to Russell 2000® Index and Raises $4.4M in ATM Offering
GlobeNewswire · 06/30 14:00
CohBar Added To Russell 200 Index
Benzinga · 06/30 13:01
CohBar Founder Dr. Nir Barzilais New Book AGE LATER Reveals that Aging Can Be Seen as a Preventable Disease
GlobeNewswire · 06/17 14:00
CohBar to Hold 2020 Annual Shareholder Meeting and Investor Update June 16, 2020
GlobeNewswire · 06/02 14:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CWBR

CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.
More

Webull offers kinds of CohBar Inc stock information, including NASDAQ:CWBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CWBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CWBR stock methods without spending real money on the virtual paper trading platform.